Evolving Strategies for Leveraging SGLT2 Inhibitor Therapy in Type 2 Diabetes

Download All
Get patient-specific guidance on T2D treatment options and insights on managing CVD and CKD risk.
Martin J. Abrahamson, MD, FACP
Zachary T. Bloomgarden, MD, MACE
Anne Peters, MD
Richard E. Pratley, MD
Robert S. Zimmerman, MD

Interactive Decision Support Tool

Access expert recommendations to individualize treatment and minimize CV, HF, and CKD risks for patients T2D

Martin J. Abrahamson, MD, FACP Zachary T. Bloomgarden, MD, MACE Anne Peters, MD Richard E. Pratley, MD Robert S. Zimmerman, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: December 9, 2020 Expired: December 8, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by an independent educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue